Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | MMP1 | P03956 | 3/20 | 0.40 |
| ▸ | MMP2 | P08253 | 3/20 | 0.40 |
| ▸ | MMP8 | P22894 | 3/20 | 0.40 |
| ▸ | MMP3 | P08254 | 2/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6956635 | 1.00 | LMNA (0.50) | LMNAALDH1A1MAPK1BCHEMMP1 | |
| SCHEMBL6956637 | 1.00 | LMNA (0.50) | LMNAALDH1A1MAPK1BCHEMMP1 | |
| SCHEMBL7068510 | 0.92 | XPNPEP2 (0.43) | LMNAALDH1A1MAPK1MMP1MMP2 | |
| SCHEMBL6954392 | 0.92 | XPNPEP2 (0.43) | LMNAALDH1A1MAPK1MMP1MMP2 | |
| SCHEMBL6954395 | 0.92 | XPNPEP2 (0.43) | LMNAALDH1A1MAPK1MMP1MMP2 | |
| SCHEMBL7067800 | 0.88 | ALDH1A1 (0.50) | ALDH1A1 | |
| SCHEMBL6954284 | 0.88 | ALDH1A1 (0.50) | ALDH1A1 | |
| SCHEMBL6955027 | 0.88 | HPGD (0.44) | LMNAALDH1A1MAPK1BCHEMMP1 | |
| SCHEMBL7065389 | 0.88 | HPGD (0.44) | LMNAALDH1A1MAPK1BCHEMMP1 | |
| SCHEMBL6954285 | 0.88 | ALDH1A1 (0.50) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232985-A1 | Succinoylamino heterocycles as inhibitors of a beta protein production | THOMPSON LORIN A (US) | 2003-12-18 | — | — | US | disclosed |
| US-20030073701-A1 | Succinoylamino heterocycles as inhibitors of a beta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073701-A1 | Succinoylamino heterocycles as inhibitors of a beta protein production | APP, BACE1, APH1A | LMNA 911/4885ALDH1A1 3091/4885MAPK1 1873/4885 |
| US-20030232985-A1 | Succinoylamino heterocycles as inhibitors of a beta protein production | APP, BACE1, APH1A | LMNA 911/4885ALDH1A1 3091/4885MAPK1 1873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.